
Santanu Maji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6673025/publications.pdf Version: 2024-02-01



ςαντανίι Μαιί

#	Article	IF	CITATIONS
1	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacological Research, 2020, 155, 104695.	7.1	29
2	Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12324-12331.	7.1	28
3	MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein. Cancer and Metastasis Reviews, 2020, 39, 769-781.	5.9	23
4	Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor. Molecular Cancer Therapeutics, 2019, 18, 1997-2007.	4.1	19
5	Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
6	SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress. Life Sciences, 2021, 287, 120141.	4.3	5
7	Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein. International Journal of Molecular Sciences, 2022, 23, 72.	4.1	5
8	Theranostic Tripartite Cancer Terminator Virus for Cancer Therapy and Imaging. Cancers, 2021, 13, 857.	3.7	4
9	Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor. Frontiers in Oncology, 2022, 12, 812560.	2.8	2
10	Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter. Cancers, 2022, 14, 1497.	3.7	1